Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
clinical trials
4
×
life sciences
national blog main
national top stories
biotech
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
bolt biotherapeutics
bristol-myers squibb
cancer
cell therapy
crispr
diagnostics
eli lilly
gene therapy
gilead sciences
glaxosmithkline
immunotherapy
johnson & johnson
What
bio
4
×
new
4
×
drug
roundup
later
advantages
analysis
approval
bar
biogen’s
biopharma
biopharmaceutical
biotech
bring
brings
companies
company
congress
congressional
convo
crispr
develop
diseases
earlier
employing
executives
expect
failures
feud
gamble
genetic
goldfinch
group
ipo
isn’t
kidney
known
lead
littered
market
Language
unset
Current search:
bio
×
new
×
" clinical trials "
×
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More